An observational study in Gestational Diabetes Mellitus (GDM), Pregnancy Complications and History of Bariatric Surgery, sponsored by Burak Deniz Aydoğdu. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Burak Deniz Aydoğdu · Observational
Among 52 studies in Diabetes, Gestational with a site in Turkey — 9 open to participants now, 12 under way, none of them phase 3. Diabetes, Gestational · Turkey.
Among the 52 studies in Diabetes, Gestational with a site in Turkey, this one is the 15th largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2026, is one of 24 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 46th registered.
877 studies on the registry are indexed under Diabetes, Gestational; 200 are open to participants now.
Browse Diabetes, Gestational studies →9 of the 52 studies in Diabetes, Gestational with a site in Turkey are open now. Recruiting first, the newest first:
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Sites in Turkey
Ages 18–50 · Women only · Healthy volunteers
Izmir Ataturk Training and Research Hospital · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Izmir Katip Celebi University · Sites in Turkey
Ages 18+ · Women only
Umraniye Education and Research Hospital · Sites in Turkey
Ages 18–39 · Women only
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 136 Diabetes, Gestational studies recruiting now, 62 (46%) set no upper age limit and 72 (53%) stop at 75 or younger; 13 take children under 18; 62 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 175 across 289 observational studies indexed under Diabetes, Gestational.
Median enrollment 85 across the 28 interventional studies, 100 across the 24 observational. Of the 37 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 52 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Burak Deniz Aydoğdu as lead sponsor.
Burak Deniz Aydoğdu has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07750431Samsun UniversityThe Role of Progesterone Membrane Receptors in the Development of Gestational Diabetes Mellitus | 2027-01-01 |
| NCT07067411Yeditepe UniversityGamified Education for Diabetes Self-Management in GDM | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Diabetes, Gestational with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational diabetes mellitus (GDM) is associated with significant maternal and fetal complications. The standard diagnostic test for GDM is the 75-gram oral glucose tolerance test (OGTT). However, pregnant women who have undergone bariatric surgery may not tolerate OGTT due to dumping syndrome and gastrointestinal side effects. This creates diagnostic challenges in this specific population.
The aim of this prospective observational study is to evaluate whether routinely measured glycemic markers, including fasting blood glucose, postprandial blood glucose, HbA1c, and urinary glucose levels, can predict the development of gestational diabetes mellitus and related pregnancy complications in women with prior bariatric surgery.
Pregnant women aged 18-50 years with a history of bariatric surgery will be enrolled and followed throughout pregnancy. The predictive value of glycemic markers for GDM, macrosomia, and polyhydramnios will be analyzed using multivariable logistic regression models.
This study aims to provide alternative diagnostic approaches for GDM screening in pregnant women who are unable to tolerate OGTT and to contribute to improving maternal and perinatal outcomes in this growing patient population.
Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with increased risks of maternal and perinatal morbidity. Early identification and appropriate management are essential to reduce adverse outcomes such as macrosomia, polyhydramnios, and cesarean delivery.
The standard diagnostic approach for GDM is the 75-gram oral glucose tolerance test (OGTT). However, women with prior bariatric surgery frequently experience intolerance to glucose loading due to dumping syndrome, which limits the reliability and feasibility of OGTT in this population. Consequently, alternative diagnostic strategies are required.
This prospective observational cohort study will be conducted at Prof. Dr. Cemil Taşcıoğlu City Hospital between February 2026 and December 2027. Pregnant women aged 18-50 years with a history of bariatric surgery will be enrolled during the first or second trimester. Participants will be categorized according to OGTT tolerance (tolerated vs. not tolerated/refused).
Baseline demographic characteristics including maternal age, gravidity, parity, obstetric history, and educational status will be recorded. Glycemic parameters assessed during routine antenatal follow-up will include fasting plasma glucose, postprandial glucose, HbA1c levels, and urinary glucose measurements. Second and third trimester ultrasound findings will be documented. Pregnancy outcomes including diagnosis of GDM, macrosomia (birth weight >4000 g), and polyhydramnios will be recorded.
The primary objective is to evaluate the predictive value of routine glycemic markers for GDM. Secondary objectives include assessing their association with macrosomia and polyhydramnios.
Statistical analyses will be performed using SPSS version 27. Continuous variables will be summarized as mean ± standard deviation or median (interquartile range) depending on distribution. Comparisons between groups will be performed using the Mann-Whitney U test. Multivariable logistic regression models will be used to determine independent predictors of GDM and other pregnancy complications after adjustment for potential confounders.
This study aims to provide evidence for alternative screening approaches in pregnant women with prior bariatric surgery who are unable to tolerate OGTT and to improve clinical decision-making in this growing patient population.
The study population consists of pregnant women aged 18-50 years with a history of bariatric surgery prior to conception who were followed at the Department of Obstetrics and Gynecology of Prof. Dr. Cemil Taşcıoğlu City Hospital. Eligible participants have documented glycemic parameters during the first and/or second trimester (including fasting plasma glucose, HbA1c, urine glucose and/or oral glucose tolerance test results) and available third trimester and/or delivery records. Only singleton pregnancies with complete clinical data are included.
Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women with a history of bariatric surgery who tolerate and complete the 75-gram oral glucose tolerance test during pregnancy.
Pregnant women with a history of bariatric surgery who are unable to tolerate or refuse the 75-gram oral glucose tolerance test during pregnancy.
Development of Gestational Diabetes Mellitus (GDM)
Diagnosis of gestational diabetes mellitus based on standard 75-gram oral glucose tolerance test (OGTT) criteria or clinical diagnostic criteria in women unable to tolerate OGTT.
Time frame: Between 24 and 28 weeks of gestation
Polyhydramnios
Polyhydramnios diagnosed by ultrasound during pregnancy as documented in routine antenatal follow-up.
Time frame: Between 24 and 40 weeks of gestation
Plan to share: No — Individual participant data (IPD) will not be shared due to institutional policies and national data protection regulations. Although this is a prospective study, the informed consent obtained from participants does not include permission for public data sharing. All collected data will be analyzed in de-identified form and handled in accordance with ethical approval and applicable data protection laws.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.
Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 22 months is below that.
Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.